Safety of intravenous iron in hemodialysis patients

Hemodialysis International

Volumn 21, Issue , 2017, Pages S93-S103

  Li, Xiaojuan ^a,b   Kshirsagar, Abhijit V ^b   Brookhart, M Alan ^a  

^a The University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; infections; safety issues

Indexed keywords

IRON;

ALLERGIC REACTION; BACTERIAL GROWTH; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DRUG SAFETY; END STAGE RENAL DISEASE; HEMODIALYSIS; HUMAN; REVIEW; ANEMIA; DRUG HYPERSENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION;

ANEMIA; DRUG HYPERSENSITIVITY; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 85017474143     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12558     Document Type: Review

References (77)

1. Eschbach JW, Adamson JW. Anemia of end-stage renal disease. Kidney Int. 1985; 28:1–5.
2. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001; 12:2465–2473.
3. Gaweda AE, Ginzburg YZ, Chait Y, et al. Iron dosing in kidney disease: Inconsistency of evidence and clinical practice. Nephrol Dial Transplant. 2015; 30:187–196.
4. Macdougall IC, Bircher AJ, Eckardt K, et al. Iron management in chronic kidney disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int. 2016; 89:28–39.
5. Kapoian T, O'Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008; 19:372–379.
6. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007; 18:975–984.
7. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085–2098.
8. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:2071–2084.
9. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361:2019–2032.
10. Centers for Medicare & Medicaid Services, HHS. Medicare program; end-stage renal disease prospective payment system. Final rule. Fed Regist. 2010; 75:49029–49214.
11. Freburger JK, Ng LJ, Bradbury BD, et al. Changing patterns of anemia management in US hemodialysis patients. Am J Med. 2012; 125:906–914.e9.
12. Miskulin DC, Zhou J, Tangri N, et al. Trends in anemia management in US hemodialysis patients 2004-2010. BMC Nephrol. 2013; 14:264.
13. Fuller DS, Pisoni RL, Bieber BA, et al. The DOPPS practice monitor for U.S. dialysis care: Update on trends in anemia management 2 years into the bundle. Am J Kidney Dis. 2013; 62:1213–1216.
14. Karaboyas A, Zee J, Morgenstern H, et al. Understanding the recent increase in ferritin levels in United States dialysis patients: Potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol. 2015; 10:1814–1821.
15. Agarwal R, Vasavada N, Sachs NG, et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004; 65:2279–2289.
16. Brewster UC. Intravenous iron therapy in end-stage renal disease. Semin Dial. 2006; 19:285–290.
17. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62:1524–1538.
18. Maynor L, Brophy DF. Risk of infection with intravenous iron therapy. Ann Pharmacother. 2007; 41:1476–1480.
19. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21:378–382.
20. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011; 8:2101–2141.
21. Kidney Disease: Improving Global Outcomes Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 2:279–335.
22. Locatelli F, Bárány P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement. Nephrol Dial Transplant. 2013; 28:1346–1359.
23. Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013; 62:849–859.
24. Moist LM, Troyanov S, White CT, et al. Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013; 62:860–873.
25. Krishnan M, Weldon J, Wilson S, Goyhkman I, Van Wyck D. Effect of maintenance iron protocols on ESA dosing and anemia outcomes (abstract 153). Am J Kidney Dis. 2011; 57:A55.
26. Nephrology News & Issues. Implementing an IV iron administration protocol within a dialysis organization. Available from: http://www.nephrologynews.com (accessed date: March 22, 2015).
27. Miskulin DC, Tangri N, Bandeen-Roche K, et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol. 2014; 9:1930–1934.
28. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980; 243:1726–1731.
29. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: Guidance for risk minimization and management. Haematologica. 2014; 99:1671–1676.
30. Michael B, Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002; 61:1830–1839.
31. Aronoff GR, Bennett WM, Blumenthal S, et al. Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens. Kidney Int. 2004; 66:1193–1198.
32. Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients: A comparison of preparations. Transfus Altern Transfus Med. 2007; 1:1–7.
33. Sav T, Tokgoz B, Sipahioglu MH. Is there a difference between allergic potencies of the iron sucrose and low molecular weight iron dextran?. Ren Fail. 2007; 29:423–426.
34. Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010; 85:650–654.
35. Vecchio LD, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. 2016; 9:260–267.
36. Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015; 314:2062–2068.
37. European Medicines Agency. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001833.jsp&mid=WC0b01ac058004d5c1 (accessed date: December 15, 2016).
38. FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). US Food and Drug Administration, Drug Safety Communications. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM440336.pdf (accessed date: May 11, 2015).
39. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. J Am Soc Nephrol. 2006; 1:S19–S23.
40. Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: Evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol. 2004; 24:949–954.
41. Zager RA, Johnson AC, Hanson SY, et al. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002; 40:90–103.
42. Toblli JE, Cao G, Oliveri L, et al. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model. Arzneimittelforschung. 2011; 61:399–410.
43. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int. 2004; 65:1802–1809.
44. Sullivan JL. Do hemochromatosis mutations protect against iron-mediated atherogenesis?. Circ Cardiovasc Genet. 2009; 2:652–657.
45. Li JJ, Meng X, Si HP, et al. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol. 2012; 32:1158–1166.
46. Kautz L, Gabayan V, Wang X, et al. Testing the iron hypothesis in a mouse model of atherosclerosis. Cell Rep. 2013; 5:1436–1442.
47. Reis KA, Guz G, Ozdemir H, et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J. 2005; 46:255–264.
48. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 106:2212–2217.
49. van der Weerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2013; 28:3062–3071.
50. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial. 2009; 22:636–643.
51. Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: A meta-analysis. Am J Nephrol. 2014; 39:130–141.
52. Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005; 16:3070–3080.
53. Kuo KL, Hung SC, Lin YP, et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS One. 2012; 7:e50295.
54. Kshirsagar AV, Freburger JK, Ellis AR, et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One. 2013; 8:e78930.
55. Bailie GR, Larkina M, Goodkin DA, et al. Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015; 87:162–168.
56. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004; 15:1623–1632.
57. Gupta A, Zhuo J, Zha J, et al. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol. 2010; 11:16.
58. Parkkinen J, von Bonsdorff L, Peltonen S, et al. Catalytically active iron and bacterial growth in serum of haemodialysis patients after I.V. iron-saccharate administration. Nephrol Dial Transplant. 2000; 15:1827–1834.
59. Barton PA, Pai MP, Depczynski J, et al. Non-transferrin bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol. 2006; 26:304–309.
60. Anker SD. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361:2436–2448.
61. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015; 88:905–914.
62. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014; 29:2075–2084.
63. Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis. 1999; 34:S47–S52.
64. Besarab A, Frinak S, Yee J. An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol. 1999; 10:2029–2043.
65. Eschbach J, Adamson JW. Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy. Kidney Int Suppl. 1999; 69:S35–S43.
66. Ishida JH, Johansen KL. Iron and infection in hemodialysis patients. Semin Dial. 2014; 27:26–36.
67. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials. BMJ. 2013; 347:f4822.
68. Brookhart MA, Freburger JK, Ellis AR, et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol. 2013; 24:1151–1158.
69. Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin variability, serumferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014; 86:845–854.
70. Zitt E, Sturm G, Kronenberg F, et al. Iron supplementation and mortality in incident dialysis patients: An observational study. PLoS One. 2014; 9:e114144.
71. Tangri N, Miskulin DC, Zhou J, et al. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: A comparative effectiveness analysis from the DEcIDE-ESRD study. Nephrol Dial Transplant. 2015; 30:667–675.
72. Sirken G, Raja R, Rizkala AR. Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. Clin Nephrol. 2006; 66:348–356.
73. Diskin CJ, Stokes TJ, Dansby LM, et al. Is systemic heparin a risk factor for catheter-related sepsis in dialysis patients? An evaluation of various biofilm and traditional risk factors. Nephron Clin Pract. 2007; 107:c128–c132.
74. Brookhart MA, Li X, Kshirsagar AV. What are the considerations in balancing benefits and risks in iron treatment?: Balancing benefits and safety with intravenous iron treatment. Semin Dial. 2016; 30:25–27.
75. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA. The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med. 2013; 126:541.
76. Freburger JK, Ellis AR, Kshirsagar AV, Wang L, Brookhart MA. Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: A replication study. BMC Nephrol. 2014; 15:154.
77. Michels WM, Jaar BG, Ephraim PL, et al. Intravenous iron administration strategies and anemia management in hemodialysis patients. Nephrol Dial Transplant. 2016; 0:1–9.